New drug combo shows promise for tough breast cancer

NCT ID NCT05143229

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-stage trial tests two drugs, alpelisib and sacituzumab govitecan, together in people with advanced HER2-negative breast cancer that has spread or come back. The main goal is to find the safest dose and see how the body handles the drugs. 18 adults are taking part in this study at the University of Kansas Medical Center.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The University of Kansas Cancer Center

    Westwood, Kansas, 66205, United States

  • The University of Kansas Cancer Center - Indian Creek

    Overland Park, Kansas, 66211, United States

  • The University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri, 64064, United States

  • The University of Kansas Cancer Center - North

    Kansas City, Missouri, 64154, United States

  • The University of Kansas Cancer Center - North Kansas City Hospital

    Kansas City, Missouri, 64116, United States

  • The University of Kansas Cancer Center - Overland Park

    Overland Park, Kansas, 66210, United States

  • The University of Kansas Clinical Research Center

    Fairway, Kansas, 66205, United States

Conditions

Explore the condition pages connected to this study.